Literature DB >> 9971778

Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among lymphocryptoviruses of Old World primates.

I K Ruf1, A Moghaddam, F Wang, J Sample.   

Abstract

Epstein-Barr virus (EBV), the only known human lymphocryptovirus (LCV), displays a remarkable degree of genetic and biologic identity to LCVs that infect Old World primates. Within their natural hosts, infection by these viruses recapitulates many key aspects of EBV infection, including the establishment of long-term latency within B lymphocytes, and is therefore a potentially valuable animal model of EBV infection. However, it is unclear whether these LCVs have adopted or maintained the same mechanisms used by EBV to express essential viral proteins, such as EBNA-1, in the face of cell-mediated repression of EBV gene expression that occurs upon establishment of the asymptomatic carrier state. To address this issue, we determined whether the endogenous LCVs of baboon (Cercopithecine herpesvirus 12) and rhesus macaque (Cercopithecine herpesvirus 15) have the functional equivalent of the EBV promoter Qp, which mediates exclusive expression of EBNA-1 during the restricted programs of EBV latency associated with the carrier state. Our results indicate that (i) both the baboon and rhesus macaque LCVs have a genomic locus that is highly homologous to the EBV Qp region, (ii) key cis-regulatory elements of Qp are conserved in these LCV genomes and compose promoters that are functionally indistinguishable from EBV Qp, and (iii) EBNA-1 transcripts identical in structure to EBV Qp-specific EBNA-1 mRNAs are present in nonhuman LCV-infected cells, demonstrating that these Qp homologs are indeed utilized as alternative EBNA-1 promoters. These observations indicate that the molecular mechanisms which regulate EBV gene expression during restricted latency have been conserved among the LCVs. The contribution of these mechanisms to viral persistence in vivo can now be experimentally tested in nonhuman primate models of LCV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9971778      PMCID: PMC104440     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B cells from peripheral blood.

Authors:  H Chen; P Smith; R F Ambinder; S D Hayward
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

2.  The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.

Authors:  R Longnecker; C L Miller; X Q Miao; A Marchini; E Kieff
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated.

Authors:  J Sample; E B Henson; C Sample
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

4.  The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Authors:  A L Lear; M Rowe; M G Kurilla; S Lee; S Henderson; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

5.  Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes.

Authors:  L Qu; D T Rowe
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

6.  Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site.

Authors:  J Sample; L Brooks; C Sample; L Young; M Rowe; C Gregory; A Rickinson; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

7.  Differential expression of Epstein Barr viral transcripts for two proteins (TP1 and LMP) in lymphocyte and epithelial cells.

Authors:  P R Smith; B E Griffin
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

8.  Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.

Authors:  L Brooks; Q Y Yao; A B Rickinson; L S Young
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

9.  Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.

Authors:  R Khanna; S R Burrows; M G Kurilla; C A Jacob; I S Misko; T B Sculley; E Kieff; D J Moss
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

10.  Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.

Authors:  R J Murray; M G Kurilla; J M Brooks; W A Thomas; M Rowe; E Kieff; A B Rickinson
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

View more
  20 in total

1.  Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.

Authors:  N W Blake; A Moghaddam; P Rao; A Kaur; R Glickman; Y G Cho; A Marchini; T Haigh; R P Johnson; A B Rickinson; F Wang
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Transcriptional regulatory properties of Epstein-Barr virus nuclear antigen 3C are conserved in simian lymphocryptoviruses.

Authors:  Bo Zhao; Rozenn Dalbiès-Tran; Hua Jiang; Ingrid K Ruf; Jeffery T Sample; Fred Wang; Clare E Sample
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses.

Authors:  R Peng; A V Gordadze; E M Fuentes Pananá; F Wang; J Zong; G S Hayward; J Tan; P D Ling
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Complete genomic sequence of an Epstein-Barr virus-related herpesvirus naturally infecting a new world primate: a defining point in the evolution of oncogenic lymphocryptoviruses.

Authors:  Pierre Rivailler; Young-Gyu Cho; Fred Wang
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 5.  Molecular evolution of the gamma-Herpesvirinae.

Authors:  D J McGeoch
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

6.  Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1.

Authors:  L Zhang; J S Pagano
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 7.  Simian homologues of Epstein-Barr virus.

Authors:  F Wang; P Rivailler; P Rao; Y Cho
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

8.  Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.

Authors:  R Leskowitz; M H Fogg; X Y Zhou; A Kaur; E L V Silveira; F Villinger; P M Lieberman; F Wang; H C Ertl
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

9.  CTCF prevents the epigenetic drift of EBV latency promoter Qp.

Authors:  Italo Tempera; Andreas Wiedmer; Jayaraju Dheekollu; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2010-08-12       Impact factor: 6.823

Review 10.  Epigenetic regulation of EBV and KSHV latency.

Authors:  Horng-Shen Chen; Fang Lu; Paul M Lieberman
Journal:  Curr Opin Virol       Date:  2013-04-16       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.